Početna › Neuroblastom › New York
Kliničke studije za Neuroblastom u državi New York
13 studija za Neuroblastom traži sudionike na lokacijama u državi New York.
Gradovi u državi New York
Službeni tekst studije (engleski)
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Albany Medical Center, Albany
- Roswell Park Cancer Institute, Buffalo
- NYU Langone Hospital - Long Island, Mineola
- i još 7
U tijeku regrutacijaFaza 3
Do 30 godina · Oba spola · Ažurirano 2. lis 2026. · NCT06172296A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
- Memorial Sloan Kettering Cancer Center, New York
U tijeku regrutacijaFaza 2Zdravi dobrovoljci dobrodošli
Sve dobne skupine · Oba spola · Ažurirano 30. ruj 2026. · NCT04936529Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Memorial Sloan Kettering Cancer Center ( Site 1010), New York
- New York Medical College ( Site 1023), Valhalla
U tijeku regrutacijaFaza 1/2
6 Months – 25 Years · Oba spola · Ažurirano 17. ruj 2026. · NCT06395103N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
- Memorial Sloan Kettering Cancer Center, New York
U tijeku regrutacijaFaza 2
18 Months – 19 Years · Oba spola · Ažurirano 28. kol 2026. · NCT06528496Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Albany Medical Center, Albany
- Maimonides Medical Center, Brooklyn
- Roswell Park Cancer Institute, Buffalo
- i još 8
U tijeku regrutacijaFaza 3
365 Days – 30 Years · Oba spola · Ažurirano 25. kol 2026. · NCT03126916Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
U tijeku regrutacijaFaza 1/2
12 Months – 30 Years · Oba spola · Ažurirano 25. kol 2026. · NCT04851119SPEARHEAD-3 Pediatric Study
- Memorial Sloan Kettering Kids, New York
U tijeku regrutacijaFaza 1/2
Od 2 do 21 godina · Oba spola · Ažurirano 11. kol 2026. · NCT05642455A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
- Memorial Sloan Kettering Suffolk-Commack (Consent only), Commack
- Memorial Sloan Kettering Westchester (Consent only), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- i još 1
U tijeku regrutacijaFaza 2
Sve dobne skupine · Oba spola · Ažurirano 28. srp 2026. · NCT06057948Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- Memorial Sloan Kettering Cancer Center, New York
U tijeku regrutacijaFaza 2
Od 1 godina i više · Oba spola · Ažurirano 29. svi 2026. · NCT00107289Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
- New York Medical College, Valhalla
U tijeku regrutacijaFaza 1
Od 1 do 30 godina · Oba spola · Ažurirano 15. tra 2026. · NCT04308330Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
- Albert Einstein College of Medicine, Children's Hospital at Montefiore, The Bronx
- New York Medical Center/ Maria Fareri Children's Hospital, Valhalla
U tijeku regrutacijaFaza 2
Od 1 do 50 godina · Oba spola · Ažurirano 13. ožu 2026. · NCT01804634Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome
- Memorial Sloan Kettering Cancer Center, New York
U tijeku regrutacijaOpažajna studija
Sve dobne skupine · Oba spola · Ažurirano 15. lis 2025. · NCT00588068A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
- Children's Hospital at Montefiore, The Bronx
U tijeku regrutacijaFaza 2
18 Months – 40 Years · Oba spola · Ažurirano 12. kol 2025. · NCT05135975Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.